Potential antidepressant-like effects of the biased 5HT1A receptor agonist NLX101 in rats
In recent years, major depressive disorder has been studied from many pathophysiolog-ical perspectives and has been concluded as a multifactorial disease with complex inter-actions between multiple signaling systems. The serotoninergic and noradrenergic sys-tems are implicated in the depression symp...
| Autor: | |
|---|---|
| Formato: | tesis de maestría |
| Fecha de publicación: | 2021 |
| País: | España |
| Recursos: | Universidad de Cantabria (UC) |
| Repositorio: | UCrea Repositorio Abierto de la Universidad de Cantabria |
| Idioma: | inglés |
| OAI Identifier: | oai:repositorio.unican.es:10902/23462 |
| Acesso em linha: | http://hdl.handle.net/10902/23462 |
| Access Level: | acceso abierto |
| Palavra-chave: | Depression Serotonin 5HT1A receptor Behavior Biased Agonism Western Blot |
| Resumo: | In recent years, major depressive disorder has been studied from many pathophysiolog-ical perspectives and has been concluded as a multifactorial disease with complex inter-actions between multiple signaling systems. The serotoninergic and noradrenergic sys-tems are implicated in the depression symptoms. In general, antidepressants are created to improve serotoninergic system; however, leading to changes in homeostasis mecha-nisms. Well known fact that classical antidepressants work only partially and with a de-layed onset has triggered the emergence of novel antidepressant agents with supposedly more precise mechanisms of action and less unwanted side effects. They increase sero-tonin levels in raphe nucleus that can lead to activation of autoreceptors and consequent decrease of serotonin in frontal cortex. A lot of attention has gained serotonin 1A hetero-receptor and its associated mechanisms. NLX101 is a novel serotonin 1A receptor biased agonist that exhibits antidepressant characteristics in animal models. It has shown a func-tional selectivity for specific G-protein alpha subunits and downstream pathways. Here, we reveal that systemic single dose administration of NLX101 shows antidepressant-like activity in Forced Swim Test, stimulates glutamate and dopamine release in prefrontal cortex dialysate, and increases phosphorylated protein, m-TOR, Glu1A, expression in prefrontal cortex. Overall, NLX101 shows rapid, but not sustained antidepressant-like ac-tion at low doses. |
|---|